Retinal Vasculitis After Administration of Brolucizumab Resu
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
A 77-year-old woman had acute visual acuity loss in her right eye following her second administration of brolucizumab for neovascular age-related macular degeneration. She had previously been treated with both bevacizumab and aflibercept since her initial diagnosis in 2018. She had never had any intraocular inflammation with either medication. Her baseline visual acuity was 20/50 OD and 20/30 OS. She initially noted blurry vision immediately after her injection with brolucizumab but believed it would be temporary. She presented to the office 3 weeks later, on her return from a cruise. Her visual acuity was 20/200 OU.

An anterior segment examination was clinically significant for keratic precipitates. Posteriorly, minimal vitreous cells were noted, with clinically significant boxcarring of the retinal arteries. Fluorescein angiography was performed. Early-phase angiogram images are notable for vascular pruning and arterial and venous filling defects. Retinal ischemia with nonperfusion and late disc leakage were noted on later images of the angiogram. A vitreous sample was taken and sent for a Gram stain, bacterial and fungal cultures, and a viral polymerase chain reaction. All had negative findings. Her left eye was unremarkable. This constellation of findings on examination and angiography was consistent with an occlusive retinal vasculitis. She started receiving difluprednate 4 times a day and 40 mg of prednisone per day, without visual improvement at a 2-week follow-up. She subsequently tapered off of both drugs.